Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial

Publikation

Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial

Hermanns, Norbert; Heinemann, Lutz; Kulzer, Bernhard; u. a. (2025): Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes : insights from the randomized controlled HypoDE trial, in: Diabetes research and clinical practice, Amsterdam: Elsevier, Jg. 224, Nr. 112228, S. 1–8, doi: 10.1016/j.diabres.2025.112228.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Heinemann, Lutz
Schäfer, Arne
Jacobsen, Malte
Titel der Zeitschrift
Diabetes research and clinical practice
ISSN
1872-8227
0168-8227
Verlagsangabe
Elsevier : Amsterdam
Erscheinungsjahr
2025
Jahrgang
224
Heft
112228
Sprache(n)
Englisch
DOI
Abstract

Aims:

This study re-analysed data from the HypoDE trial to assess the prevalence of nocturnal hypoglycaemia, evaluate the impact of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycaemia, and explore their influence on severe hypoglycaemia (SH).

Methods:

The HypoDE trial was a randomized controlled trial involving 141 adults with type 1 diabetes, impaired hypoglycaemia awareness, or prior SH. Participants were randomized to CGM (Dexcom G5) or self-monitoring of blood glucose (control). Outcomes included the percentage of time spent in hypoglycaemia (<3.9 mmol/L, <3.0 mmol/L), episode duration, and SH incidence.

Results:

At baseline, nocturnal hypoglycaemia (<3.0 mmol/L) exposure exceeded daytime by 1.4 percentage points (95 % CI 0.6–2.2; p < 0.002), with episodes lasting 30.7 min longer (CI 21.5–39.9). Using CGM, these differences disappeared (<3.0 mmol/L: 0.3 percentage points, CI 0.7–1.3), while they persisted in the control group. Daytime hypoglycaemia significantly increased SH risk (IRR 1.10 per percentage point, CI 1.01–1.21; IRR 1.04 per minute, CI 1.01–1.07).

Conclusions:

CGM effectively reduced nocturnal and daytime hypoglycaemia. Without CGM, nocturnal hypoglycaemia contributes to daytime risks, while daytime hypoglycaemia elevates SH risk. Expanding CGM access and addressing nocturnal hypoglycaemia in resource-limited settings are critical.

Trial registrationClinicaltrials.gov: NCT02671968.

Freie Schlagwort(e)
Diabetestechnology
Continuous glucose monitoring
Nocturnal hypoglycaemia
Severe hypoglycemia
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
CU 1000
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
23.05.2025
Projekt(e)

Permalink: https://fis.uni-bamberg.de/handle/uniba/108385 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 15.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.